RTW Biotech Lands $75M Financing Deal with Aquestive

RTW Biotech Opportunities has signed a $75 million financing deal with Aquestive. The Guernsey-based biotech firm focuses on transformative assets with high growth potential in biopharmaceuticals and medical technology. The investment will be used to create a diversified portfolio of life sciences companies across various therapeutic categories and product types. RTW Investments, LP will manage the portfolio.

RTW Biotech Opportunities Ltd, a Guernsey-based investment fund focused on transformative assets with high growth potential in biopharmaceuticals and medical technology, has signed a strategic $75 million funding agreement with Aquestive Therapeutics Inc. [1]

The investment, contingent on the U.S. FDA approval of Anaphylm, a sublingual epinephrine film, will support Aquestive's efforts to commercialize this potential breakthrough treatment for severe allergic reactions, including anaphylaxis. Anaphylm is the first orally delivered film using a novel prodrug of epinephrine in clinical development [2].

RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm, will manage the investment. The funding agreement is structured to provide capital to support the commercialization of Anaphylm, with RTW receiving a tiered, single-digit percentage of annual U.S. net sales, subject to a cap [1].

Aquestive, a pharmaceutical company with four commercial products on the market, develops orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies [2].

This strategic partnership reflects RTW's belief in the commercial prospects of Anaphylm as a rescue treatment for patients experiencing severe allergic reactions. The funding will become available upon FDA approval of Anaphylm and the fulfillment of certain refinancing and other conditions related to the company's existing debt [1].

Cantor Fitzgerald & Co served as the exclusive financial advisor to Aquestive on the royalty financing transaction. The investment is expected to support the company's growth and innovation in the life sciences sector [1].

References:
[1] https://investorshub.advfn.com/market-news/article/14768/aquestive-therapeutics-shares-rise-after-75-million-funding-deal
[2] https://www.investegate.co.uk/announcement/rns/rtw-venture-fund-limited-npv-gbp---rtwg/strategic-funding-agreement-with-aquestive/9062296